Close menu




March 28th, 2022 | 11:20 CEST

Who profits by it? Shares! Alibaba, wallstreet:online, Steinhoff

  • Investments
Photo credits: pixabay.com

Buy, sell or hold? The stock market is sometimes turbulent. The war in Ukraine and its economic side effects, in particular, can cause events to spiral out of control. Investors have to react quickly to limit losses or seize opportunities. We highlight three stocks and explain how they are doing in the current unrest.

time to read: 3 minutes | Author: Nico Popp
ISIN: ALIBABA GR.HLDG SP.ADR 8 | US01609W1027 , WALLSTREET:ONLINE INH ON | DE000A2GS609 , STEINHOFF INT.HLDG.EO-_50 | NL0011375019

Table of contents:


    Alibaba: Russia business hurts

    Alibaba's stock has been under pressure for months. First, Beijing fired back against its flagship company, suspecting too much power in the hands of overly progressive people, then came the imbalance in China's real estate market and the associated blanket aversion of Western investors to China. Since Russia invaded Ukraine, Alibaba's stock has shown a somewhat mixed picture; it was going up in the first days of the war, but now the price is increasingly crumbling. The reason: The sanctions against Russia: Meanwhile, it became known that AliExpress Russia is an important pillar of Alibaba in e-commerce. This business could be made more difficult in the course of the sanctions.

    China is also in a quandary. Putin wants more support, but nothing more than verbal support has come around so far. China even spoke out quite diplomatically against war in general. And yet the market is pricing in a bloc formation. On the one side, it could be Europe with the US, and on the other, the warring party Russia with China. But is that realistic? China is dependent on the West and sells many of its products there. Also, China is the second-largest creditor of the US - the dependence on the dollar is also present in Beijing, and so is the interdependence. With Alibaba stock losing more than 50% over the past year, investors should slowly but surely throw up their hands. However, one should not forget that timing is twice as tricky in market phases such as the current one. However, Alibaba remains a well-positioned company.

    wallstreet:online: Prices back at the level of a year ago

    wallstreet:online is also well positioned. The media company has long been more than just a provider of stock market forums and financial websites. With its Smartbroker, wallstreet:online has long been one of Germany's leading providers and plans to continue growing strongly. The escalating national debts and the empty pension funds are drivers of the private age precaution. More and more former savers are making these investments on the stock market in times of zero interest rates and custody fees. Since wallstreet:online offers financial media and brokerage, synergy effects arise. Many brokers have to spend a lot of money on marketing. At wallstreet:online, customer acquisition also works via its numerous pages. In the long term, there are even plans to address the users of Smartbroker even more strongly when it comes to reacting to company announcements and media reports. If readers could trade directly from articles, that would benefit wallstreet:online's sales.

    In any case, the volatile market phase is a gift for experienced traders. When prices shoot up and come back down, multiple trades and an active trading strategy pay off. After the Company reported a record year in 2021, sales are expected to increase by another 25% in 2022. Figures for deposit openings during the first months of the year also show that the current market environment is not dampening enthusiasm for the stock market. Since the share is trading today at the level of a year ago, but the Company is operationally further ahead, investors should pay closer attention to the value. wallstreet:online is an institution on the German capital market and will remain so.

    Steinhoff only makes lawyers and brokers wealthy

    An institution among gamblers is undoubtedly the troubled furniture group Steinhoff. For months, the legal dispute with shareholders caused a stir. Steinhoff was involved in an accounting scandal years ago, and shareholders demanded compensation. In the meantime, the dispute has been postponed, but it is far from over. The claims still exist, and a solution must be found by next year at the latest. Because of this, Steinhoff's operational situation is again coming to the fore. The Company could also be forced to sell shareholdings. The ups and downs at Steinhoff are only something for experienced gamblers. However, all in all, only the brokers involved and the lawyers accompanying the legal disputes surrounding the furniture group are profiting.


    While the Steinhoff share is a hot potato and Alibaba is currently considered somewhat risky, wallstreet:online could even profit from the back and forth on the markets. However, it will be necessary for the markets to return to a solid upward trend in the medium term. wallstreet:online is perfectly positioned to benefit from a good stock market sentiment.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read